Step-by-Step Guide to Accessing TKIs for CML
Patients in New Foundland and Labrador
This guide provides step-by-step instructions for Chronic Myeloid Leukemia (CML) patients in New Foundland and Labrodor, to access Tyrosine Kinase Inhibitors (TKIs). It includes details on navigating provincial drug programs, private insurance, and additional resources.
1. General Overview
Accessing TKIs in New Foundland and Labrador Island involves a combination of private insurance, provincial drug programs, and patient assistance programs. These steps ensure that patients receive life-saving medications without financial barriers.
2. Step-by-Step Instructions
Step 1: Consult with Your Oncologist
Your oncologist will determine the most appropriate TKI for your treatment and provide the prescription. They may also initiate the application process for provincial drug plans or private insurance.
Step 2: Submit to Private Insurance
If you have private insurance, submit your TKI prescription to your insurer. Private insurance will typically cover a portion of the drug cost. Obtain an Explanation of Benefits (EOB) document from your insurer for any remaining costs.
Step 3: Apply to Provincial Drug Programs
Newfoundland and Labrador
• Apply to the Newfoundland and Labrador Prescription Drug Program (NLPDP).
• Coverage for TKIs is available under the Access or Foundation Plans.
• Submit a special authorization request with support from your oncologist.
Step 4: Use Patient Assistance Programs
Pharmaceutical companies offer patient assistance programs to help with reimbursement navigation and financial support. Contact these programs for additional help:
• Novartis Tasigna (Nilotinib) & Scemblix (Asciminib):
Sentia – PSP contact information:
Phone: 1-855-736-8421
Fax: 1-866-636-8421
Email: psp@sentia-exp.ca
• Bosutinib (Bosulif): Pfizer Liaison (1-844-616-6888)
•Ponatinib (Iclusig): Paladin Labs Distribution Program for patients. Contact 1.877.318.4462 or Email: PalSupport@bayshore.ca
Step 5: Follow Up with Monitoring and Renewals
Regular follow-up appointments with your oncologist are essential to monitor treatment response. Ensure that your applications to provincial drug programs are renewed annually or as required.
Step 6: Generic Drugs
There are currently two generic TKI’s on the Market in Canada. These drugs may be covered through your private insurance/employer sponsored drug plan and RAMQ, but they DO NOT have a pharmaceutical company sponsored support program.
1. Gleevec (Imatinib): Offered by Apotex or Teva,
2. Dasatinib (Sprycel): Offered by Teva Canada Limited, Appotex Inc. and Taro Pharmaceuticals
3. Additional Resources
• Provincial Cancer Societies: Provide support and guidance for patients navigating access to treatments.
• Pharmacists: Assist with insurance claims and provide information on co-pay programs.
• Healthcare Providers: Work closely with your oncologist and care team to ensure timely access to medications.
Conclusion:
Accessing TKIs for CML treatment in Atlantic Canada involves coordination between private insurance, provincial drug programs, and patient assistance programs. By following these steps, patients can navigate the system effectively and ensure access to life-saving treatments.